Torrent Pharma approves September quarter and half-year results

Board & Shareholder Meetings View source PDF Explain this filing

TORNTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹4524.40

prior close

₹4561.10

announcement price

After-mkt

timing

Nifty 100market+0.7%-0.2% vs market

Pharmaceuticals peers, median of 174sector+1.2%-0.6% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty 100 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

-0.2

15m

-0.3

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+0.7-0.2+1.2-0.6

Next day

+2.2+1.0+1.3+3.1-0.9

+1.2pendingpending+4.8-3.6

—————

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Audited standalone and reviewed group results for the period ended 30 September 2026 were approved. Quarter revenue rose 50 percent to Rs 4,145 crore; profit fell 17 percent to Rs 498 crore. Half-year revenue rose 54 percent to Rs 8,303 crore, while profit fell to Rs 990 crore from Rs 1,148 crore. Group half-year revenue rose 53 percent to Rs 9,900 crore, but profit fell 3 percent to Rs 1,100 crore. JB Pharma merger issued 41.92 million shares.

Likely market impact

Strong revenue growth is positive, but lower profit and dilution from 41.92 million new shares may limit near-term gains for shareholders.